利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.027 秒)

    Methods and systems for inhibiting vascular inflammation
    1.
    发明授权
    Methods and systems for inhibiting vascular inflammation 有权

    公开(公告)号：US10441747B2

    公开(公告)日：2019-10-15

    申请号：US14605865

    申请日：2015-01-26

    申请人： Mercator MedSystems, Inc.

    发明人： Kirk Patrick Seward

    IPC分类号： A61M25/00 ,  A61M37/00 ,  A61M25/10 ,  A61L29/16 ,  A61L31/16 ,  A61M5/158 ,  A61B5/01 ,  A61B5/021 ,  A61B5/053 ,  A61B5/145 ,  A61B5/00

    摘要： Methods and kits for delivering pharmaceutical agents to an adventitia and other regions outside an external elastic lamina (EEL) surrounding a blood vessel utilize a catheter having a needle. The needle is positioned in up to 5 mm beyond the EEL and delivers an amount of a pharmaceutical agent sufficient to circumferentially permeate around the blood vessel and, in many cases, extend longitudinally and radially along the blood vessel. Confirmation that a delivery aperture of the needle lies beyond the EEL may be required before delivering the pharmaceutical agent. In one example, catheters are used to deliver dexamethasone and other anti-inflammatory agents to a peripheral vasculature and other vasculature to treat peripheral vascular disease and other conditions.

    TREATMENT OF RENAL HYPERTENSION OR CAROTID SINUS SYNDROME WITH ADVENTITIAL PHARMACEUTICAL SYMPATHETIC DENERVATION OR NEUROMODULATION
    3.
    发明申请
    TREATMENT OF RENAL HYPERTENSION OR CAROTID SINUS SYNDROME WITH ADVENTITIAL PHARMACEUTICAL SYMPATHETIC DENERVATION OR NEUROMODULATION 有权
    治疗晚期高血压或心律失常综合征具有优良的药物治疗或神经修复

    公开(公告)号：US20130287698A1

    公开(公告)日：2013-10-31

    申请号：US13895668

    申请日：2013-05-16

    申请人： Mercator MedSystems, Inc.

    发明人： Kirk Patrick Seward

    IPC分类号： A61K9/00 ,  A61M25/00 ,  A61M5/44

    CPC分类号： A61M25/1002 ,  A61K9/0019 ,  A61K31/155 ,  A61K31/395 ,  A61K45/06 ,  A61M5/00 ,  A61M5/007 ,  A61M5/44 ,  A61M25/00 ,  A61M25/0084 ,  A61M2025/009 ,  A61K2300/00

    摘要： Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict medication regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient.

    摘要翻译： 交感神经穿过肾动脉周围的外膜，对调节系统性高血压至关重要。 这些神经的多动症可引起肾性高血压，一种普遍存在于成年人群中的30-40％的疾病。 高血压可以用神经调节剂（如血管紧张素转换酶抑制剂，血管紧张素II抑制剂或醛固酮受体阻断剂）治疗，但需要遵守严格的药物治疗方案，并且通常不能达到目标血压阈值以降低主要心血管事件的风险。 这里介绍一种微创溶液，通过将神经毒性或神经阻滞剂局部输送到外膜来减少肾动脉周围交感神经的活动。 这些试剂的延长洗脱也可以完成，以便对患者进行定制。

    Dual modulus balloon for interventional procedures
    6.
    发明授权
    Dual modulus balloon for interventional procedures 有权

    公开(公告)号：US10561816B2

    公开(公告)日：2020-02-18

    申请号：US15691138

    申请日：2017-08-30

    申请人： Mercator MedSystems, Inc.

    发明人： Kirk Patrick Seward ,  Isidro M. Gandionco ,  David Gandionco

    IPC分类号： A61M25/00 ,  A61M5/158 ,  A61M5/00 ,  A61M25/10 ,  A61M25/01

    摘要： A device for interventional surgical or medical procedures is presented. The device is generally in the form of a balloon and is used to position itself or other working elements up against or through lumen walls in the body. The balloon is comprised of at least two materials of different elastic modulus, which allows for a flexible but relatively non-distensible, unfolding component of the balloon as well as an elastomeric, inflatable component of the balloon. The elastomeric component is fixedly attached to the flexible but relatively non-distensible component and together they form a pressure vessel that can be inflated within the lumens of the body.

    Treatment of renal hypertension or carotid sinus syndrome with heated fluid sympathetic denervation or neuromodulation
    9.
    发明授权
    Treatment of renal hypertension or carotid sinus syndrome with heated fluid sympathetic denervation or neuromodulation 有权
    治疗肾性高血压或颈动脉窦综合征，加热液体交感神经去神经调节或神经调节

    公开(公告)号：US09011879B2

    公开(公告)日：2015-04-21

    申请号：US13895668

    申请日：2013-05-16

    申请人： Mercator MedSystems, Inc.

    发明人： Kirk Patrick Seward

    IPC分类号： A61M25/00 ,  A61K47/00 ,  A61K45/06 ,  A61K9/00 ,  A61K31/155 ,  A61K31/395 ,  A61M25/10 ,  A61M5/00 ,  A61M5/44

    CPC分类号： A61M25/1002 ,  A61K9/0019 ,  A61K31/155 ,  A61K31/395 ,  A61K45/06 ,  A61M5/00 ,  A61M5/007 ,  A61M5/44 ,  A61M25/00 ,  A61M25/0084 ,  A61M2025/009 ,  A61K2300/00

    摘要： Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict medication regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient.

    摘要翻译： 交感神经穿过肾动脉周围的外膜，对调节系统性高血压至关重要。 这些神经的多动症可引起肾性高血压，一种普遍存在于成年人群中的30-40％的疾病。 高血压可以用神经调节剂（如血管紧张素转换酶抑制剂，血管紧张素II抑制剂或醛固酮受体阻断剂）治疗，但需要遵守严格的药物治疗方案，并且通常不能达到目标血压阈值以降低主要心血管事件的风险。 这里介绍一种微创溶液，通过将神经毒性或神经阻滞剂局部输送到外膜来减少肾动脉周围交感神经的活动。 这些试剂的延长洗脱也可以完成，以便对患者进行定制。

    Treatment of hypertension by renal vascular delivery of guanethidine
    10.
    发明授权
    Treatment of hypertension by renal vascular delivery of guanethidine 有权

    公开(公告)号：US11083877B2

    公开(公告)日：2021-08-10

    申请号：US16529494

    申请日：2019-08-01

    申请人： Mercator MedSystems, Inc.

    发明人： Kirk Patrick Seward

    IPC分类号： A61K9/19 ,  A61M25/10 ,  A61K31/155 ,  A61K31/395 ,  A61K45/06 ,  A61M25/00 ,  A61K9/00 ,  A61M5/00 ,  A61M5/44

    摘要： Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or sympathetic nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient.